
http://www.exicuretx.com
Exicure, Inc. Company Intro
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for immuno-oncology, genetic disorders, and other indications. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. Exicure, Inc. has collaboration agreements with Allergan plc; DERMELIX, LLC; and Purdue Pharma L.P. The company was founded in 2011 and is headquartered in Skokie, Illinois.
Industry
Healthcare
Exicure, Inc. Headquaters
8045 Lamon Avenue
Skokie,60077
United States
Exicure, Inc. Share price
22 Jan 2021 02:54 GMT
$2.3500
0.08 (3.52 %)
Exicure, Inc. Market cap
$202.353 M
WMC RANKING
2021
Exicure, Inc. # 153
BiotechnologyLatest Exicure, Inc. News
08 Jan 2021
Global Interleukin 1 (IL1) Market 2020 Insights, Share, Growth ...
Exicure Inc Immune Response BioPharma Inc ... As a market research company, we take pride in equipping our clients with insights and data that holds the ...
08 Jan 2021
Interleukin 1 (IL1) Market Trends, Top Manufactures ...
Competitive dashboard: Optimum Therapeutics LLC, Cell Medica Ltd, AbbVie Inc, ... Inc, TWi Biotechnology Inc, Swedish Orphan Biovitrum AB, Exicure Inc, ...
08 Jan 2021
Global Interleukin 1 (IL1) Market 2020 Insights, Share, Growth ...
Exicure Inc Immune Response BioPharma Inc ... As a market research company, we take pride in equipping our clients with insights and data that holds the ...
WMC Market Score
WMC Market to Revenue Score
Exicure, Inc. Market Financials
Revenue, Expenses, Profit
Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
Exicure, Inc. | USD | $16,783 | $39,868 | $-21,964 | $2,024M | 153 |
Regeneron Pharmaceuticals, Inc. | USD | $9,243,500 | $5,152,600 | $3,156,000 | $571,390B | 1 |
Alexion Pharmaceuticals, Inc. | USD | $5,862,400 | $2,588,400 | $956,600 | $345,270B | 2 |
Vertex Pharmaceuticals Incorporated | USD | $5,991,128 | $2,596,854 | $2,690,691 | $620,550B | 3 |
ALK-Abello A/S | USD | $3,383,000 | $1,831,000 | $43,000 | $271,640B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Exicure, Inc. Social Followers vs Top 4 Industry Competitors
Exicure, Inc. Post vs Top 4 Industry Competitors
Exicure, Inc. Digital Footprint By Size vs Top 4 Industry Competitors
Exicure, Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
Exicure, Inc. WMC Market Score Calculations
Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
Exicure, Inc. | 0.18 | 0 | 0 | 0 | 0 | 0 | 0 |
Regeneron Pharmaceuticals, Inc. | 100 | 66.33 | 29.44 | 100 | 0 | 0 | 100 |
Alexion Pharmaceuticals, Inc. | 63.42 | 16.28 | 100 | 60 | 0 | 0 | 90.10 |
Vertex Pharmaceuticals Incorporated | 64.81 | 100 | 8.77 | 86 | 0 | 0 | 99.40 |
ALK-Abello A/S | 36.60 | 0 | 0 | 0 | 0 | 0 | 0 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge